RCS - Creo Medical Group - Creo Medical receives King’s Award for Enterprise

Creo MedicalAnnouncement

07/05/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240507:nRSG3363Na&default-theme=true

RNS Number : 3363N  Creo Medical Group PLC  07 May 2024

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Creo Medical receives King's Award for Enterprise in Innovation

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of minimally invasive surgical endoscopy, announces that it is
to receive a King's Award for Enterprise in Innovation, at an event to be held
at Windsor Castle on 9 July 2024.

 

Established by Royal Warrant in 1965, The King's Awards for Enterprise is the
UK's most prestigious business awards to recognise and encourage achievements
in the fields of Innovation, International Trade, Sustainable Development and
Promoting Opportunity through social mobility.

 

During the reception, His Majesty will meet Creo's Chief Executive Officer,
Craig Gulliford, as well as a diverse group of winners from across the United
Kingdom, with recipients of the award able to use The King's Awards emblem for
the next five years on their products and to promote their services.

 

 

Creo Medical Group plc is an innovative and growing medical technology
company. It has developed CROMA, an advanced energy electrosurgical platform
and a range of novel, miniaturised devices that are used through the small
working channels of endoscopes, enabling the most minimally invasive surgery
where operations are performed from inside the body. Creo's Speedboat device
harnesses CROMA's cutting and coagulation capabilities to remove cancerous and
pre-cancerous growths and complex lesions in the bowel, oesophagus and
stomach. By providing a solution that reduces the risks associated with
conventional surgical procedures, Creo's Speedboat allows clinicians to
precisely lift, resect and coagulate tissue with a single device, removing
lesions from within the gastrointestinal tract in one piece. This means
patients can be treated as day cases under mild sedation instead of more
invasive surgery requiring general anaesthetic and multiple days in hospital.

 

Creo's products deliver benefits to patients, reduce waiting lists, free up
resources, and significantly lower hospital costs. NHS Supply Chain recently
confirmed net cash savings of £687k were generated for an NHS Trust from 130
procedures using Creo's core Speedboat technology. Creo's technology is patent
protected, and its devices are used daily across dozens of countries and in
over 20 NHS hospitals.

 

Craig Gulliford, Chief Executive Officer of Creo Medical, said: "We are
delighted to receive this award from His Majesty The King at a Royal reception
in recognition of our team's outstanding work, dedication and achievements
towards innovation in healthcare. I would like to put on record my thanks to
the whole team in their daily commitment to improving patient outcomes,
cutting waiting times and saving the NHS money. Innovation has always been at
the heart of Creo, and the increasing adoption of our pioneering technology by
clinicians around the world, reflects the significant benefits that innovation
can bring to both patients and healthcare systems."

 

Enquiries:

 

 Creo Medical Group plc                             www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                 +44 (0)1291 606 005

 Cavendish Capital Markets Limited                  +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson (Sales)

 Deutsche Numis (Joint Broker)                      +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR                                        Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen                           Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 Phillip Marriage                                   +44 (0)7867 984 082

 

About Creo Medical (www.creomedical.com (http://www.creomedical.com) )

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

About The King's Award

 

The King's Awards for Enterprise are the most prestigious awards for UK
businesses, previously known as The Queen's Awards for Enterprise. The Awards
recognise and celebrate business excellence in innovation, international
trade, sustainable development and promoting opportunity (through social
mobility).

 

Awardees receive a Grant of Appointment and a trophy presented by one of HM
Lord-Lieutenants, and are able to display the Award Emblem for up five years.
They also have access to a thriving alumni network of previous award winners.

 

Recipients of the Award often state that their achievement has opened new
doors for them in terms of securing new contracts, venturing into new markets,
and further developing their business.

 

https://www.gov.uk/kings-awards-for-enterprise
(https://www.gov.uk/kings-awards-for-enterprise)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFZGGKRVZGDZM